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Abstract 
Drug-induced phospholipidosis (DIPL) is characterised by an increase in the phospholipid content of the 
cell and the accumulation of drugs and lipids inside the lysosomes of affected tissues, including in the 
liver. While of uncertain pathological significance for patients, the condition remains a major impediment 
for the clinical development of new drugs. Human Sandhoff disease (SD) is caused by inherited defects of 
the β subunit of lysosomal β-hexosaminidases (Hex) A and B, leading to a large array of symptoms, 
including neurodegeneration and ultimately death by the age of four in its most common form. The 
substrates of Hex A and B, gangliosides GM2 and GA2, accumulate inside the lysosomes of the CNS and 
in peripheral organs. Given that both DIPL and SD are associated with lysosomes and lipid metabolism in 
general, we measured the hepatic lipid profiles in rodent models of these two conditions using untargeted 
LC-MS to examine potential commonalities. Both model systems shared a number of perturbed lipid 
pathways, notably those involving metabolism of cholesterol esters, lysophosphatidylcholines, 
bis(monoacylglycero)phosphates, and ceramides. We report here profound alterations in lipid metabolism 
in the SD liver. In addition, DIPL induced a wide range of lipid changes not previously observed in the 
liver, highlighting similarities with those detected in the model of SD and raising concerns that these lipid 
changes may be associated with underlying pathology associated with lysosomal storage disorders. 
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Introduction 
Drug-induced phospholipidosis (DIPL) is a condition caused by drug treatment, leading to an increase in 
the cellular phospholipid content. It was first detected in 1948 in rats after long-term treatment with 
chloroquine, an anti-malarial agent (1). DIPL has been observed in vitro, and in vivo in animals and 
humans. In this disorder, cells can appear vacuolated when observed by light microscopy, although this is 
not always evident, and there is an accumulation of foamy macrophages containing phagocytosed 
material (2,3). The key characteristic feature of DIPL is the observation, by electron microscopy, of 
intracellular uni- or multi-centric lamellar bodies (4). Lamellar bodies, also called myelin bodies, contain 
mostly undegraded phospholipids and the administered drug that caused DIPL (5). 
Several hundred cationic amphiphilic drugs (CADs) have the potential to cause DIPL (2,6–8). These 
agents belong to different drug classes, including antidepressants such as Prozac, antibiotics, 
antipsychotics and cholesterol-lowering drugs, such as Simvastatin. However, they all share a common 
structure: one or several hydrophobic rings and a hydrophilic chain containing an amine group positively 
charged at neutral pH (6,9). CADs have been intensely developed by pharmaceutical industries because 
they can easily cross biological membranes, including the blood-brain barrier, due to their amphiphilic 
character. Because they are weak bases, CADs are protonated in the acidic environment of the lysosome 
and can no longer cross membranes, they are therefore trapped within the organelle (6). Although it has 
been studied for more than 65 years, the potential toxicity and mechanisms of DIPL remain unclear.   
Progress has been made to identify biomarkers of DIPL; bis(monoacylglycero)phosphate (BMP, also 
known as lyso-bisphosphatidic acid) (16:0/18:1) has been suggested as a biomarker in tissues from rats 
treated with amiodarone (10) and BMPs as a class found to be increased in concentration post-DIPL 
(10,11). BMPs are negatively charged phospholipids principally found in the inner membranes of late 
endosomes and lysosomes (12) with an unusual sn-1:sn-1’ configuration in which each glycerol moiety is 
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esterified by a fatty acid. They stimulate the degradation of glycosphingolipids in these organelles (13) 
and participate in the transport of cellular cholesterol and its degradation (14–16). 
The two main hypotheses to explain the increase in cellular phospholipid content after induction of DIPL 
are impaired degradation of phospholipids by direct or indirect inhibition of phospholipase activity (7,17–
20), and increased phospholipid synthesis (21,22). However, other metabolic pathways have also been 
found to be up-regulated in DIPL, including stimulation of lipogenesis in a time- and dose-dependent 
manner (22), increased cholesterol biosynthesis (19,23,24), and concerted changes in phospholipid 
degradation, and cholesterol and fatty acid syntheses (19). Moreover, in this latter study N-
acylsphingosine amidohydrolase 1 (ASAH1), also called lysosomal acid ceramidase, was identified as a 
marker transcript of DIPL (19). 
DIPL shares common features with some lysosomal storage disorders (LSDs), including Niemann-Pick 
type C (NPC) and Fabry diseases. In NPC disease, caused by a defect in NPC 1 or NPC 2 proteins that are 
responsible for the cellular traffic of cholesterol, both cholesterol and sphingolipids accumulate (25). A 
similar observation has been made in the liver of rats treated with chloroquine (26) and  treatment with 
amiodarone in vitro (27). Fabry disease is characterised by the accumulation of globotriasylceramide due 
to a deficiency in α-galactosidase. A misdiagnosis of Fabry disease has been reported in a rheumatoid 
arthritis patient treated with chloroquine, due to the similar morphological features observed in biopsies 
from this lysosomal disease to those in DIPL (28). Furthermore, the concentration of several BMP species 
has also been found to be increased in a variety of lysosomal diseases (29,30), including BMP (22:6/22:6) 
in the brain of a mouse model of neuronal ceroid lipofuscinosis (30). 
Sandhoff disease (SD), another LSD, is caused by a mutation in the HEXB gene, which encodes for the β 
subunit of β-hexosaminidases (Hex), leading to a deficiency in Hex A and B (31). Hex are lysosomal acid 
hydrolases which cleave N-acetylglucosamine and N-acetylgalactosamine residues from a variety of 
substrates, mainly glycopeptides, glycolipids, glycosaminoglycans and ganglioside GM2 (31,32). In SD 
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patients, accumulation of gangliosides GM2 and the sphingolipid GA2 is detected throughout the CNS as 
well as peripherally to a lesser degree. Gangliosides are complex sphingolipids composed of a ceramide 
backbone, polysaccharide units and, for most species, a sialic acid moiety. They are principally abundant 
in the CNS (33,34); their concentration being one to two orders of magnitude lower in other tissues (35). 
In visceral tissues, increases in globoside concentrations have been detected previously (36). There is a 
large array of symptoms in SD patients, including decrease in motor, mental and visual abilities, alteration 
of the vision, macrocephaly, seizures, liver enlargement, slight bone deformation and neurodegeneration, 
ultimately leading to death by four years of age in the most severe form of the disease (31,37,38). Hexb -/- 
mice are a widely used model to study the pathogenesis and develop treatment for SD (39–42). 
In the present study, we have explored the metabolic alterations in the liver of Hexb -/- mice and those 
induced by treatment with chloroquine, a hepatic phospholipidosis-inducer, in rats (300 mg/kg/day for 5 
days) using an untargeted lipidomic approach. Comparison of the two lysosomal lipidoses by exploring 
their lipid profiles has facilitated the identification of perturbed biochemical pathways which immediately 
suggest common pathological mechanisms. 
 
  
6 
 
Material and methods 
Animal studies 
All animal studies were ethically reviewed and carried out in accordance with the UK Animals (Scientific 
Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals (for the DIPL 
study). 
 Rats for the study of DIPL 
A seven-day study was conducted on male Sprague Dawley rats (n = 9 per group, 10 weeks old at the 
beginning of the study). The control group was orally dosed with vehicle (1% aqueous methylcellulose) 
and the chloroquine group received an oral dose of 300 mg/kg/day. The dose was chosen as it was known 
to produce lesions associated with DIPL in liver tissue (2,6,26,43,44). Animals were killed by 
exsanguination via the abdominal aorta under isoflurane anaesthesia. Rats given 1% aqueous 
methylcellulose were killed at day 7, whereas rats treated with chloroquine were killed at day 5, due to 
intercurrent deaths and clinical signs observed up to that point. 
 Hexb -/- mice 
The congenic SD mouse model (strain: B6; 129S-Hexbtm1Rlp), developed by disruption of the Hexb gene 
(45), was obtained from the Jackson Laboratory, USA and had been interbred for more than 20 
generations. To maintain the colony, homozygous males were crossed with heterozygous females, or 
heterozygous animals were inter-crossed. Mice (n = 5 for both the SD and the control groups) were fed ad 
libitum and killed by asphyxiation at four months of age, the humane end point. Tissues were dissected 
and frozen immediately on dry ice.  
 
Metabolite extraction 
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For the study of DIPL in rats, 100 mg of liver tissue was used for extraction, while 50 mg of liver tissue 
from mice was taken for the investigation of SD. Metabolites were extracted according to the following 
procedure described by Le Belle and co-workers (46). As an initial extraction solvent, 6.0 mL of a 
methanol/chloroform mixture in a 2:1 ratio (v/v) was used per gram of tissue. The mixture was 
homogenised in a TissueLyser (Qiagen, Germany) and sonicated for 15 min at room temperature (22 °C). 
To the mixture was added 2.0 mL chloroform and 2.0 mL water per gram of tissue to form an emulsion. 
The samples were then centrifuged for 20 min at 20,844 x g at 22 °C to generate distinct organic and 
aqueous fractions and a protein pellet. The organic and aqueous layers were individually removed and 
transferred to separate tubes. The entire extraction process was repeated on the protein pellet and any 
remaining aqueous or organic fraction in order to perform a double extraction to maximize recovery. 
Fractions prepared during the second extraction were combined with those from the first. The organic 
layer was placed in a fume hood under a stream of nitrogen gas to evaporate the solvent and once dry 
stored at -80 °C until analysis. 
 
LC-MS analysis 
The open profiling of lipids was performed using the dried lipid fraction obtained after metabolite 
extraction (10 mg tissue equivalent). Samples were injected onto an LC column prior to MS to provide 
compound separation by chromatography. 
For the DIPL sample analysis, chromatography was performed on an Acquity UPLC® (Waters Inc., 
USA) using an Acquity UPLC® High Strength Silica (HSS) T3 column (1.8 µm x 2.1 mm x 100 mm) 
(Waters Inc., USA) at 55 °C. The lipid fraction was dissolved in methanol/chloroform mixture (1:1, v/v) 
and 5 µL of this was injected onto the column. 
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For the analysis of the SD samples, chromatography was performed on an Acquity UPLC® Charged 
Surface Hybrid (CSH) C18 column (1.7 µm x 2.1 mm x 100 mm) (Waters Inc., USA) at 55 °C. The lipid 
fraction from each sample was diluted in a mixture of isopropanol/acetonitrile/water (2:1:1 v/v/v) and 2 
µL of this was injected onto the column. 
The LC parameters were the same for both studies. The flow rate was 0.4 mL/min. Mobile phase A was 
composed of 60% acetonitrile and 40% water with the addition of 10 mM ammonium formate to improve 
ionisation. Mobile phase B was 10% acetonitrile and 90% isopropanol with 10 mM ammonium formate. 
The chromatographic gradient progressed from 40% mobile phase B up to 99% B over 18 min, followed 
by 2 min of equilibration at 40% B. 
MS was performed on a Xevo G2 Q-TOF mass spectrometer (Waters Inc., USA) in positive and negative 
ion modes using a scan time of 0.2 s, a collision energy of 6 V for each single scan, and a collision ramp 
from 25 to 40 V for the fragmentation function in positive ion mode and from 30 to 50 V in negative ion 
mode. Capillary voltage was 2 kV, sampling cone was 30 V, extraction cone was 3.5 V and source 
temperature was 120 °C. Leucine enkephalin was used as a lockmass to improve mass accuracy 
throughout the analysis and 5 mM sodium formate was used to calibrate the instrument prior to analysis 
(the maximum threshold for mass difference between the measured mass and the exact mass was set at 5 
ppm). 
Chromatograms were processed using the MarkerLynx XS tool from the MassLynx software (version 4.1, 
Waters Inc., USA) using peak detection analysis with the following parameters: retention time: 0 to 18 
min, mass range: 50 to 1800 Da for the DIPL study and 50 to 2300 Da for the SD study, tolerance for the 
mass value: 0.05 Da, minimum intensity to consider for a spectral peak: 2000 counts. Data were de-
isotoped, normalised to the internal standard (PC 17:0/17:0) intensity, and metabolites were identified 
using the following online databases: www.lipidmaps.org (Lipid Metabolites and Pathways Strategies), 
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www.hmdb.ca (Human Metabolome Database) and www.genome.jp/kegg/ (the Kyoto Encyclopaedia of 
Genes and Genomes). 
 
Gene expression measurement using quantitative PCR 
The extraction of RNA from 15 mg rat liver was carried out using the RNeasy lipid tissue mini kit 
(Qiagen, Germany). Briefly, liver tissue was homogenised with 1 mL of QIAzol Lysis Reagent using a 
TissueLyser (Qiagen, Germany) operating at 20 Hz for 2 min. The lysate was then used for RNA 
extraction. After the addition of 200 µL chloroform to each homogenate, each sample was centrifuged at 
12,000 x g for 15 min in a centrifuge 5424 (Eppendorf). After collection of the upper aqueous phase, one 
volume of 70% ethanol was added to each sample and vortex-mixed. Each sample was transferred to an 
RNeasy Mini Spin column and centrifuged for 15 s at 12,000 x g. The column was then washed with 350 
µL Buffer RW1 and centrifuged for 15 s at 12,000 x g. The DNA was eliminated with 80 µL DNase 1 
incubation mix directly placed onto the RNeasy spin column membrane and incubated at room 
temperature (22 °C) for 15 min. The RNeasy Mini Spin column was then washed with 350 µL Buffer 
RW1 and twice with 500 µL Buffer RPE, followed by 15 s centrifugation at 12,000 x g and 2 min 
centrifugation. RNA was then eluted twice with 50 µL RNase-free water applied directly to the column, 
followed by centrifugation for 1 min at 16,000 x g. The amount of RNA yielded was subsequently 
measured on a NanoDrop spectrophotometer (Thermo Fisher Scientific, USA). 
Reverse transcription was carried out following the protocol supplied by the manufacturer. From the RNA 
isolated in the previous step, 1 µg was used as template. Genomic DNA was eliminated from the sample 
during 2 min incubation in a TC-3000 PCR Thermal cycler (Techne, UK) with 2 µL gDNA wipeout 
buffer at 42 °C. Reverse transcription was carried out during a further 15 min incubation with 1 µL 
Quantiscript reverse transcriptase, 4 µL Quantiscript RT buffer and 1 µL RT primer mix at 42 °C, and 
10 
 
then stopped by applying a temperature of 95 °C for 3 min.  It was assumed that the totality of the mRNA 
was converted to cDNA through reverse-transcription. 
cDNA synthesised through the reverse transcription of mRNA was diluted in RNase-free water to 50 ng 
of cDNA as a template for amplification. The Polymerase chain reaction (PCR)  experiment was carried 
out using TaqMan technology on a StepOnePlus instrument (Applied Biosystems, USA). The following 
method was used for DNA amplification: holding cycle at 50 °C for 2 min followed by 95 °C for 10 min; 
amplification (40 cycles) at 95 °C for 15 s followed by 60 °C for 1 min. 
Data were analysed using the StepOne software (version 2.2, Applied Biosystems, UK). Expression levels 
were normalised to the level of expression of 45S in all the control samples according to the comparative 
CT real-time PCR method by calculating the ΔCT value. The ΔCT mean value was calculated as the 
average of the ΔCT for every replicate of each sample. 
 
Multivariate statistics 
Multivariate data analysis was performed using SIMCA-P+ (versions 12.0 and 13.0, Umetrics AB, 
Sweden). Data sets were unit variance scaled prior to analysis. The pattern recognition methods used were 
principal components analysis (PCA) and partial least squares discriminate analysis (PLS-DA). 
 
Univariate statistics 
Univariate statistics were conducted using the GraphPad Prism package (version 4, GraphPad software, 
USA). The unpaired two-tailed Student’s t-test was used to compare Hexb null mice versus controls and 
chloroquine-treated rats versus controls. The significance value was set at p ≤ 0.05 to identify statistically 
significant changes. 
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Results 
To achieve the greatest coverage of the lipid species present in liver tissue, we applied a non-targeted 
lipidomic approach using LC-MS. Several lipid classes were commonly affected by DIPL and SD. 
Lysophosphatidylcholines (LPCs), cholesterol esters (CEs) and ceramides were analysed in positive ion 
mode, whereas BMPs were detected using negative ion mode. LPCs were eluted between 0.9 and 1.6 min, 
CEs between 15.2 and 16 min and ceramides between 7.4 and 14 min (Figure 1). BMP species were 
detected between 2.9 and 4.8 min (Supplemental Figure S1 and S2). The lipid species were annotated 
using their exact mass, the fragmentation spectrum, and the elution time. Moreover, we analysed 
standards for each of the lipid class described and the spectral data and retention times of the standards 
were used to confirm our annotations. Although we did not have standards for all of the species reported, 
we are at the level 2 of identification (putatively annotated compounds) according to the standards set by 
the Metabolomics Standards Initiative (47).  
 
Lysophosphatidylcholines 
The concentrations of four unsaturated LPC species were significantly increased in the liver of Hexb -/- 
mice compared to controls (Figure 1). In rat liver, after a five-day treatment with chloroquine to induce 
phospholipidosis, we detected an increase in the concentrations of LPCs 16:0, 18:0 and 18:1, whereas the 
concentration of LPC 20:4 was decreased. Furthermore, the total LPC concentration was significantly 
increased by more than 3-fold in Hexb -/- mice and almost 2-fold in DIPL rats compared to their respective 
controls. 
 
Bis(monoacylglycero)phosphates 
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The same BMP species were detected in liver from mice and rats, except for BMP (18:1/18:2), which was 
exclusively found in mice (Figure 2). The concentrations of all the BMPs were significantly increased in 
the liver of Hexb -/- mice and DIPL rats compared to the control groups, except for the concentration of 
BMP (22:6/22:6) in Hexb -/- mice which showed particularly large variations in the SD group. 
 
Cholesterol esters 
The identification of CEs was facilitated by the presence of a m/z 369 ion in the MS spectrum of the CEs, 
regardless of their acyl composition, associated with the cholesteryl head group (48,49) (Figure 3, A). In 
the Hexb -/- mice, all the CE species detected were significantly increased compared to the control mice 
(Figure 3, B). In rat liver post DIPL, the concentrations of cholesterol esters were all significantly 
increased, except for those of CEs 20:5 and 22:4 (Figure 3, C). In addition, the total hepatic CE content 
was increased more than 10-fold in Hexb -/- mice and more than 8-fold in rats post DIPL. 
 
Ceramides 
The assignment of ceramides was confirmed by the presence of a fragment ion of m/z 264 in the MS/MS 
spectrum, typical of the fragmentation of ceramides releasing their sphingoid base, sphingosine, as a 
doubly dehydrated form. The concentrations of three ceramide species, C16:0-, C20:0- and C24:1-Cer, 
were significantly increased in Hexb -/- mice compared to control animals. In rat liver post DIPL, the 
concentrations of C16:0-, C20:0-, C22:0- and C24:1-Cer were significantly increased, whereas C25:0-Cer 
concentration was decreased. In both disorders, C16:0-Cer was the most highly increased ceramide 
species (Figure 4, A and B). 
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Moreover, in the liver of both SD and DIPL animals, the ratio of long chain to very long chain (LC/VLC) 
ceramides was significantly increased compared with the controls, indicating that the composition of the 
ceramide pool was altered in a similar manner (Figure 4, C and D). 
To investigate whether the variations in the concentrations of ceramide species were associated with 
alterations to the expression of ceramide synthases (CerSs), quantitative real time-PCR (qPCR) was 
performed on the six different CerSs in liver samples from control and chloroquine-treated rats. CerS2, 
CerS4, CerS5 and CerS6 gene expressions were significantly up-regulated after treatment with 
amiodarone and chloroquine compared with controls (Figure 4, E). According to the enzyme specificities, 
the relative increases in the expression of the different CerSs in liver tissue after treatment with 
chloroquine are consistent with the alterations in ceramide species post DIPL measured by LC-MS. In SD 
liver tissue however, the gene expression of CerS1, 2, 4, 5, and 6 was not different from that of controls, 
whereas the expression of CerS3 was too low to be measured reliably (Supplemental Figure S3). 
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Discussion 
In the present study, we have used a lipidomic approach to characterise the metabolic alterations 
occurring in the liver of two rodent models of lysosomal lipidoses, SD and DIPL. The use of LC-MS has 
allowed for the sensitive detection of several lipid species that were similarly affected in these two 
models. We measured increases in BMPs, LPCs, CEs and a remodelling of the ceramide pool in favour of 
long chain ceramides suggesting both lysosomal storage disorders and DIPL have a number of common 
features. 
DIPL has been associated with a loss of lysosomal phospholipase A2 (LPLA2) function (50,51). In SD, 
the concentration of several species of LPCs was increased although a different mechanism seems to be 
responsible for these elevations; furthermore, the gene expression of the LPLA2 was found to be 
increased in an in vitro model of DIPL we have previously investigated (data not shown). 
Our results show that most BMP species detected were significantly increased in the liver, independently 
of their chain length, when Hexb was knocked-out or post DIPL. This demonstrates that increases in 
BMPs are not specific to DIPL or one particular LSD, but instead are typical of impairments of the endo-
lysosomal system as other reports have suggested (14–16,29,30). 
Mesens and co-workers have shown that cholesterol esterification was one of the pathways principally 
affected in liver tissue from rats treated with amiodarone (52). These data perfectly concur with our 
findings, showing that there is a general increase in the concentrations of cholesterol esters in rats after 
exposure to chloroquine. Moreover, this increase was also detected in Hexb -/- mice, showing 
accumulation of cholesterol esters to be closely related to lysosomal storage. 
The increases in BMPs and CEs and the changes in ceramide concentrations suggest that there is 
disruption of the endomembrane system. This system is involved in the import of molecules in 
endosomes and lysosomes, and their export through the endoplasmic reticulum and the Golgi apparatus. 
Cholesterol and sphingolipids localise together in lipid ordered domains, called lipid rafts, at the plasma 
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membrane (53–55). These domains can be endocytosed to be degraded or recycled. The increase in the 
concentrations of BMP species, markers of the late endosome and the lysosome, tends to indicate that 
there is an accumulation of late endosomes in the liver of rodents affected by DIPL and SD. This 
accumulation might be due to the impairment of fusion with the lysosome because of the storage of 
material in this organelle (drug, phospholipids or gangliosides). As the endomembrane system is highly 
dynamic and there is a continual exchange of lipid components between the organelles (56), dysfunctional 
fusion processes would cause a “traffic jam” in the cell. Moreover, if the flux through the endomembrane 
system is impaired, this could affect both cholesterol and the diverse sphingolipid species present in lipid 
ordered domains, similarly to what occurs in NPC disease (25), and might lead to the changes in ceramide 
pool composition observed. 
It is well known that BMPs stimulate the degradation of sphingolipids; their presence in high proportion 
in the inner lysosomal membrane facilitates interactions between glycosphingolipids and their degrading 
enzymes (15,57,58). Therefore, the increase in BMP concentrations in these two lysosomal lipidoses 
could be partly due to an increase in BMP synthesis in order to stimulate the catabolism of the 
accumulated lipids, as reported by Wilkening and co-workers (57,59). 
In addition, in liver tissue from Hexb -/- mice and DIPL rats, a striking remodelling of the ceramide 
content was detected. Although an alteration of sphingolipid metabolism has previously been 
hypothesised (60), it is the first time to our knowledge that ceramide concentrations have been shown to 
be affected in DIPL. Changes in ceramide concentrations have been linked to many diseases, including 
neurodegenerative diseases such as Alzheimer’s disease  (61–64). Ceramides are known to regulate many 
cellular processes, including the balance between cell survival and apoptosis (65–68). However, our 
understanding of the specific functions of individual ceramide species according to their chain length 
remains limited. Pinto and co-workers have investigated the effects of ceramide species with different 
chain length and degrees of saturation on PC membrane models (69). Notably, they have shown that 
C16:0-Cer stimulates the ability of C24:1-Cer to form gel phase domains and both these ceramide species, 
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found increased in the two lysosomal lipidoses studied, segregate into specific “flower-shaped” domains. 
Moreover, ceramides are also the precursors of sphingomyelins, known to co-localise with cholesterol in 
lipid rafts (70) and, therefore, one can presume that the alterations in the composition of the ceramide 
pool would affect the formation of microdomains and membrane properties in SD and DIPL animals.  
CerSs catalyse the production of ceramides of specific chain length from sphingosine in the salvage 
pathway of ceramide synthesis, or produce dihydroceramides from sphinganine through the de novo 
synthesis of ceramides (71,72). There are six different CerSs with overlapping functions and relative 
specificity toward acyl-CoAs, producing ceramides with specific fatty acyl chains. CerS2 catalyses the 
synthesis of VLC ceramides (22-26 carbons) (71,73,74). CerS3 shows specificity for the synthesis of long 
chain ceramides from 18 to 36 carbons (71,72,74,75). CerS5 catalyses the synthesis of C16:0-Cer (71,74) 
and has been suggested to participate in the production of C18:0-Cer (72). CerS4 and CerS1 show a 
common preference for C18:0- and C20:0-Cer (71,72). Finally, CerS6 catalyses the synthesis of C14:0-, 
C16:0- and C18:0-Cer (65,66,74).  
The alterations in CerS gene expression measured by qPCR are consistent with the changes observed in 
the concentration of ceramide species in liver tissue post DIPL. The stimulation of the expression of 
CerS2, responsible for the synthesis of VLC ceramides, after treatment with chloroquine in liver, may 
explain the increase in the concentrations of C22:0- and C24:1-Cer measured by LC-MS. In addition, the 
increase in the expression of CerS5 and CerS6 may lead to the observed increase in C16:0-Cer. The up-
regulation in the expression of CerS4 may be responsible for the increase in the concentration of C20:0-
Cer. However, one cannot speculate about the composition of the ceramide pool solely by looking at the 
activity or expression of a specific CerS because the deficiency in one CerS can lead to an increase in 
non-related ceramide species. This has been shown using CerS2 -/- mice and in knockdown experiments in 
vitro (66,76–78). In SD however, regulation of ceramide species is not caused by changes in CerS gene 
expression, as no difference was detected between controls and SD groups. 
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Besides, the results of the present study have shown that DIPL and SD share common lipid alterations, 
such as an accumulation of BMPs, an increase in CEs and in several LPC species, as well as alterations to 
ceramide metabolism. In addition, there are also similar characteristics between DIPL and various LSDs, 
including Fabry and NPC diseases, that can lead to misdiagnosis (27,28). 
Shayman and Abe compared DIPL to an acquired lysosomal disorder, describing a loss of LPLA2 activity 
due to the incorporation of CADs in the lysosomal membrane (50). LPLA2 binds to anionic 
phospholipids, such as BMPs, present in lysosomal membranes along with its substrates, phospholipids. 
This interaction between the enzyme and its substrates results in phospholipid degradation. According to 
their theory, during drug treatment, CADs are integrated to the lysosomal membrane and reduce the 
negative charge of the membrane, perturbing the interactions between LPLA2 and its substrates. This 
leads to a reduction in phospholipid degradation, resulting in DIPL (50). The authors based their 
conclusion mainly on results obtained from the generation of Lpla2 -/- mice (79). These animals are 
deficient in LPLA2 and exhibit an increase in phospholipid concentrations in alveolar and peritoneal 
macrophages accompanied by the presence of foamy macrophages and lamellar bodies, characteristic of 
DIPL. 
Lysosomal diseases are caused by a mutation in the gene coding for a lysosomal hydrolase, its activator, a 
lysosomal membrane protein or a transporter. Although all the biochemical processes and cascades 
explaining the large array of symptoms associated with these diseases have not been identified so far, the 
primary insult is always the deficiency in a lysosomal enzyme. Various metabolic pathways affected in 
DIPL models have been identified recently using microarray experiments (19,24), and confirmed in the 
present work to be associated with both DIPL and SD. However, the mechanism(s) responsible for DIPL 
are not known for certain, although some authors have identified it as a loss of LPLA2 activity (50,51), as 
stated above. However, until we can provide evidence for the impairment of LPLA2 activity by CADs in 
vivo as the primary insult with the alteration of other metabolic pathways post DIPL as a consequence of 
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this event, we cannot assert that DIPL is an acquired lysosomal storage disorder. Further investigation 
needs to demonstrate that the storage of phospholipids in DIPL and the ultra-structural changes observed 
are caused by a deficiency in a single enzyme, LPLA2, to affirm that it is an acquired lysosomal storage 
disorder. Until then, two main hypotheses regarding the mechanism of DIPL remain valid; the alteration 
of LPLA2 activity by insertion of CAD in the lysosomal membrane, leading to phospholipid 
accumulation and dysregulation of various metabolic pathways, or simultaneous alteration of multiple 
pathways by the drug. 
In conclusion, the data reported indicate that DIPL and SD share common lipid alterations in liver tissue. 
Further assessment is required to more clearly define the mechanism of DIPL. In line with previous data 
(19,20,52), we observed increases in the concentration of BMPs and cholesterol esters in rats post DIPL; 
similar changes were detected in Hexb -/- mice. Moreover, in both disorders, there was a general increase 
in LPC concentrations and changes in ceramides in favour of LC ceramides. The identification of 
metabolic pathways revealed to be altered post DIPL demonstrates that further mechanistic investigation 
is needed and that DIPL should be considered to be a much more complex disorder than is currently the 
case. 
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Figures 
 
Figure 1: Lysophosphatidylcholine concentrations in liver tissue. Metabolites were extracted from 
homogenised tissue and lysophosphatidylcholines were detected using positive ion mode LC-MS in 
control and Hexb -/- mice (A) and in control and chloroquine-treated rats (B). Results are mean +/- SEM. 
Significance level quoted for Student’s t-test * p ≤ 0.05; ** p ≤ 0.01. 
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Figure 2: Bis(monoacylglycero)phosphate concentrations in liver tissue. Metabolites were extracted from 
homogenised tissue and bis(monoacylglycero)phosphates were detected using negative ion mode LC-MS 
in control and Hexb -/- mice (A) and in control and chloroquine-treated rats (B). Results are mean +/- 
SEM. Significance level quoted for Student’s t-test * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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Figure 3: Cholesterol ester concentrations in liver tissue. Mass spectrum of cholesterol ester 18:2 
represented by (M+NH4)+ (m/z 666.6) (A). The typical MS source fragment representative of cholesterol 
esters is also present (m/z 369.4). Metabolites were extracted from homogenised tissue and cholesterol 
esters were detected using positive ion mode LC-MS in control and Hexb -/- mice (B) and in control and 
chloroquine-treated rats (C). Results are mean +/- SEM. Significance level quoted for Student’s t-test * p 
≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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Figure 4: Ceramides in liver tissue. Metabolites were extracted from homogenised tissue and ceramides 
were detected using positive ion mode LC-MS in control and Hexb -/- mice (A) and in control and 
chloroquine-treated rats (B). Ratio of long chain to very long chain ceramides in liver tissue from control 
and Hexb -/- mice (C) and from control and chloroquine-treated rats (D). Fold-change in CerS mRNA 
expression in the liver of rats treated with chloroquine compared to controls (set to 1 for each transcript) 
as measured by real-time quantitative PCR (E). Results are mean +/- SEM. Significance level quoted for 
Student’s t-test * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
 
